# What a head-to-head trial taught researchers about glucose categories

- Article ID: research-162
- Product: GLP-2 TIRZ (glp-2-tirz-691, glp-2-tirz-714)
- Canonical page: https://heritagebiolabs.com/research-library/articles/162-what-a-head-to-head-trial-taught-researchers-about-glucose-categories
- Product collection: https://heritagebiolabs.com/research-library/products/glp-2-tirz
- Product page: https://heritagebiolabs.com/product/glp-2-tirz-691
- Product page: https://heritagebiolabs.com/product/glp-2-tirz-714
- Reading focus: Study findings (Reading focus is a navigational tag, not an evidence grade.)
- Source years: 2022, 2025, 2026

> Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend.

Peptides are short chains of amino acids joined by peptide bonds. Some can mimic hormones that influence blood sugar after eating. Tirzepatide is a peptide that activates GIP and GLP-1 receptors. It appears under “GLP-2 TIRZ” in the catalog, a name distinct from its receptor targets. In a 2026 secondary analysis of SURMOUNT-5, investigators examined blood sugar measures in participants who began a weight-management trial with prediabetes. [1, 2, 3]

The original trial randomly assigned adults with obesity or overweight and a related complication to tirzepatide or semaglutide. It excluded type 2 diabetes. Its main comparison concerned weight change at 72 weeks. The later analysis focused on participants whose starting laboratory values met the study’s criteria for prediabetes. Prediabetes is a category defined by elevated glucose measurements below the criteria for diabetes. A later measurement can move a person into the study’s normal range. [1, 2]

The researchers used two measures to classify whether participants had reached normal glucose values at week 72. Fasting glucose reflects the concentration in a blood sample at the time of testing. HbA1c reflects average exposure over a longer period. The analysis reported more participants meeting its normal glucose criteria with tirzepatide than with semaglutide. It also reported a larger reduction in an estimate of insulin resistance for the tirzepatide group. The insulin resistance measure was calculated from fasting values rather than measured directly in a separate physiological test. [1]

The result is an analysis of a subset of participants in a randomized trial. Starting in the prediabetes subgroup makes the question clear and reduces the number of participants available for analysis. The authors also made statistical assumptions for missing week-72 measurements. The comparisons help show how the treatments differed on these measures under the study conditions. Classification at the end of follow-up does not indicate whether a person would stay in that category indefinitely or after stopping treatment. [1]

The original study’s weight result and the later paper’s glucose findings describe different outcomes from the same underlying trial. They should be read together to understand who took part and what was tested. The later analysis is additional evidence about a defined glucose outcome, not a new independent trial. [1, 2]

## Sources

1. Rodolfo J. Galindo et al. Reversion to normoglycemia with tirzepatide vs semaglutide in participants with obesity and prediabetes: a post hoc analysis of SURMOUNT-5. Journal of Endocrinological Investigation (publication 2026-04-20). <https://pubmed.ncbi.nlm.nih.gov/42002673/>
2. Louis J. Aronne et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. The New England Journal of Medicine (publication 2025-05-11). <https://pubmed.ncbi.nlm.nih.gov/40353578/>
3. Bingfa Sun et al. Structural determinants of dual incretin receptor agonism by tirzepatide. Proceedings of the National Academy of Sciences (publication 2022-03-25). <https://pubmed.ncbi.nlm.nih.gov/35333651/>

## Provenance

Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed. Source volume: Peptide Research Articles 033 - GLP-2 TIRZ and Glutathione.docx; article 162; content SHA-256 c05617f992a3c1001a69ea99ba1032221c16e5c3849b007d15dc9e578002fac3.
